GLP-1/glucagon dual-acting agonist (obesity / diabetes)

The dual-acting GLP-1/glucagon agonist activates both the GLP-1 and glucagon receptors, two key gut hormone receptors, and may offer better blood glucose and weight loss control than currently available single-agonist treatments. The compound builds partly on the effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans.

2018 achievements and next steps

A Phase 1b trial with the once-weekly GLP-1/Glu dual agonist for treatment of diabetes/obesity was initiated by Boehringer Ingelheim in 2018, with results expected in 2019.

The global prevalence of obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults were classified as overweight and over 600 million of these were obese.*

Collaboration with Boehringer Ingelheim

Zealand has two collaborations with Boehringer Ingelheim, where they funds all research, development and commercialization activities. Zealand is eligible to receive royalties and milestone payments as follows:

GLP-1/glucagon dual-acting agonist (2011 agreement)

  • EUR 365 million outstanding in milestone payments

  • High single-digit to low double-digit percentage royalties on global sales